Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
Charlotte von RosenstielBenedikt WiestlerBernhard HallerFriederike Schmidt-GrafJens GemptMarcus BettstetterLaura RihaniWei WuBernhard MeyerJürgen SchlegelFriederike Liesche-StarneckerPublished in: Journal of clinical pathology (2019)
The results confirm that the quantitative level of MGMT promoter methylation is a positive prognostic factor in newly diagnosed patients with GBM. The cut-off provided by the literature (</≥10%) and the calculated optimal cut-off value of 11.7% give a statistically significant separation. Hence, MethyQESD is a reliable method to calculate MGMT promoter methylation in GBM.